OBJECTIVES: The Glasgow Prognostic Score (GPS), which is calculated with C-reactive protein (CRP) and albumin (Alb) values, is a prognostic indicator for various types of cancers. However, its role in lung cancer still remains unclear, and its optimal cut-off values are controversial. Here, we evaluated the significance of the GPS and adjusted GPS (a-GPS) using our institution's cut-off values in patients undergoing resection for primary lung cancer.
INTRODUCTION
The Glasgow Prognostic Score (GPS) is an inflammation-based score that is widely accepted as a prognostic indicator in various types of cancer such as colorectal cancer, oesophageal cancer, gastric cancer, hepatocellular carcinoma and other types of cancers [1] . However, in lung cancer, most reports using the GPS focus on advanced-stage disease [1] [2] [3] [4] [5] . This issue prompted us to evaluate the GPS as a prognostic indicator in operable-stage lung cancer. In addition, there is another issue regarding the thresholds of the GPS. The GPS was originally established with standard thresholds [>1.0 mg/dl for C-reactive protein (CRP) and <3.5 g/dl for albumin (Alb)] [1, 2] . However, standard thresholds of laboratory data usually differ between institutions. Recently, several reports have described lower cut-off values of 0.3 or 0.5 mg/dl for CRP and 3.8 g/dl for Alb [6] [7] [8] [9] . These lower cut-off values may have a superior prognostic value, but are not widely accepted. In this study, we evaluated the prognostic significance of the GPS and adjusted GPS (a-GPS) using lower cut-off values in patients undergoing resection for primary lung cancer.
MATERIALS AND METHODS
A total of 1093 patients with primary lung cancer who underwent surgery at our institute between 1998 and 2012 were retrospectively analysed. Before the study, the Research Review Board at our institution examined and approved our research protocol in accordance with the Declaration of Helsinki. All patients provided written informed consent for the review of their medical charts before surgery. Fifty patients were excluded for the following reasons: lack of preoperative CRP or Alb measurements (7 patients), diagnosis of pathologically atypical adenomatous hyperplasia (5 patients) or evidence of distant metastases, dissemination or malignant effusion (38 patients). We excluded these patients because we were unable to calculate the GPS, or because good or bad prognoses were expected. The tumour stage was determined according to the seventh edition of the TNM staging system of the International Union Against Cancer [10] . The histological tumour type was determined according to the third edition of the World Health Organization classification [11] . Pathological stage 0 (3 patients) tumours were grouped into pathological stage I. The histological tumour type was classified into three categories: adenocarcinoma (Ad), squamous cell carcinoma and others, which included small cell carcinoma (23 patients), large cell carcinoma (17 patients), adenosquamous carcinoma (13 patients), pleomorphic carcinoma (9 patients) and miscellaneous (20 patients). The surgical procedures were classified into three categories: lobectomy, sublobar resection and extended resection. Sublobar resection included wedge resection and segmentectomy. Extended resection included bronchoplasty, bi-lobectomy, pneumonectomy and the combined resection of neighbouring organs, including chest wall resection. Patients' comorbidities were categorized as follows: cardiovascular diseases, cerebral diseases, hepatic diseases, renal diseases, autoimmune diseases and a past history of malignancies. Laboratory data were obtained within 1 month before the surgery. All measurements were performed at a single laboratory. To calculate the inflammation-based prognostic scores, we used two different cut-off values for CRP and Alb. For the estimation of the GPS, 1.0 mg/dl for CRP and 3.5 g/dl for Alb were used as cutoff values [1] [2] . We also evaluated the a-GPS, using the cut-off values used at our institution: 0.3 mg/dl for CRP and 3.9 g/dl for Alb. Patients who had elevated CRP and decreased Alb were allocated a score of 2, patients who had either of these were allocated a score of 1 and patients who had neither of these were allocated All variables were examined by the Mantel-Haenszel test using the general association scores. GPS: Glasgow Prognostic Score; a-GPS: adjusted Glasgow Prognostic Score. 
GPS) and the adjusted GPS (a-GPS). (A)
The 5-year OS rates for the GPS 0, 1 and 2 were 82, 55 and 55%, respectively. The log-rank test detected a significant difference in survival curves between GPS 0 and 1 (P < 0.01). There was no significant difference between GPS 1 and 2 (P = 0.66). (B) The 5-year OS rates for the a-GPS 0, 1 and 2 were 88, 67 and 59%, respectively. The log-rank test detected a significant difference in survival curves between a-GPS 0 and 1 (P < 0.01), and between a-GPS 1 and 2 (P = 0.04). *P < 0.05, N.S.: not significant. a score of 0. We also evaluated two other inflammation-based scores: the neutrophil-to-lymphocyte ratio (NLR) and the plateletto-lymphocyte ratio (PLR) [12, 13] . The NLR and the PLR were obtained from the (neutrophil absolute count)/(total lymphocyte count) and the ( platelet absolute count)/(total lymphocyte count), respectively. An NLR of >5 was defined as an elevated NLR and a PLR of >300 was defined as an elevated PLR, as reported previously [12, 13] . We calculated sensitivity, specificity, and positive and negativelikelihood ratios of the GPS and a-GPS. Events were defined as death of any cause and compiled during the entire follow-up period. Censored cases were treated as event-free. Because the GPS has three possible scores, we divided GPS results into dichotomous variables: GPS 1 + 2/GPS 0 and GPS 2/GPS 0 + 1.
The relationships between the clinicopathological features and the inflammation-based scores were assessed using analysis of variance (ANOVA) for continuous variables, the Mantel-Haenszel test using the general association scores for categorical variables and the Mantel-Haenszel test using the group mean score (ANOVA-type) statistic for ordinal variables. We evaluated the overall survival (OS) as the endpoints. The OS was calculated from the date of surgery to the time of death. The survival functions for OS were estimated by the Kaplan-Meier method and compared by the log-rank test. Univariable and multivariable analyses of the prognostic factors were assessed by Cox proportional hazards models. Multivariable analyses were performed using variables that were significantly prognostic in univariable analyses, such as age, smoking status, preoperative comorbidity, carcinoembryonic antigen (CEA), pathological stage, histological tumour type, lymphovascular invasion, surgical procedure, and the GPS and a-GPS. Because the GPS and the a-GPS might affect each other, they were evaluated using separate multivariable models. A P-value of <0.05 was considered to be statistically significant. The data were analysed using JMP Pro version 11.0.0 (SAS Institute, Cary, NC, USA) and EZR version 1.25, which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [14, 15] .
RESULTS
The clinicopathological features of the patients are summarized in Table 1 . There were 897 cases (86%) with GPS 0, 107 (10%) with GPS 1 and 39 (4%) with GPS 2, whereas there were 597 cases (57%) with a-GPS 0, 300 (29%) with a-GPS 1 and 146 (14%) with a-GPS 2. Both the high GPS and a-GPS categories tended to include older, male individuals with a history of smoking, an advanced pathological stage, non-Ad histology, lymphovascular invasion, extended surgical resection, and elevated NLR and PLR (Table 1) . Of 741 Ad patients, 44 (5.9%) had albumin <3.5 g/dl and 39 (5.2%) had CRP >1.0 mg/dl, whereas of 302 non-Ad patients, 43 (14.2%) had albumin <3.5 g/dl and 59 (19.5%) had CRP > .0 g/ dl. Although the GPS and the a-GPS were not significantly correlated with the total number of preoperative comorbidities (Table 1) , patients with a high GPS and a-GPS tended to have a history of interstitial pneumonia ( Table 2) .
The Kaplan-Meier estimates of the OS functions of the GPS (Fig. 1A) and the a-GPS (Fig. 1B) subgroups are shown. The median follow-up time was 3.8 years (quartile 1.9-6.2). The 5-year OS rates were 82, 55 and 55% with GPS 0, 1 and 2 (1 vs 0: P < 0.01; 2 vs 1: P = 0.66), respectively, and 88, 67 and 59% with a-GPS 0, 1 and 2, respectively (1 vs 0: P < 0.01; 2 vs 1: P = 0.04). The survival curves based on the a-GPS classification were more clearly separated from each other than those based on the GPS classification.
Univariable analysis revealed that the age, smoking status, preoperative comorbidities, CEA, pathological stage, histological tumour type, lymphovascular invasion, surgical procedure (extended resection), GPS, a-GPS and PLR were all significant predictors of OS (Table 3 ). Multivariable analysis revealed that the GPS [1 vs 0, hazard ratio (HR): 1.63; 2 vs 0, HR: 1.44] and the a-GPS (1 vs 0, HR: 2.00; 2 vs 0, HR: 2.10) were independent prognostic factors for OS, along with age, smoking status, preoperative comorbidities, CEA, pathological stage, histological tumour type, lymphovascular invasion and surgical procedure (Table 4) . Sensitivity, specificity, and positive and negative-likelihood ratios for the GPS and a-GPS were calculated ( Table 5 ). The a-GPS showed a higher sensitivity, lower specificity, lower positive-likelihood ratio and lower negative-likelihood ratio than the GPS.
DISCUSSION
In this study, the GPS was identified as an independent prognostic factor in operable-stage lung cancer. The a-GPS classification showed clearer prognostic distribution than the GPS classification. The prognostic impact of the GPS and a-GPS seemed to be related to several factors, which could be divided into tumour-related and -unrelated categories. Regarding the tumour-related factors, the GPS and a-GPS values were associated with oncological stage, histological type and lymphovascular invasion (Table 1) . Tumours themselves can be a cause of inflammation, especially when those locally advanced cause necrosis or obstructive pneumonia. Large tumours like these sometimes require extended surgical resection because of its invasion into neighbouring lobes or organs. Conversely, inflammation might be one cause of a more advanced oncological stage or more malignant tumour type. The close relationship between inflammation and carcinogenesis is well known [16, 17] . In this analysis, Ad patients tended to have lower GPS and a-GPS compared with non-Ad patients, but the underlying mechanism is unclear.
With regard to tumour-unrelated factors, the GPS and a-GPS showed correlations with patient age, sex, smoking status and underlying disease state (Tables 1 and 2 ). We speculate the following reasons for the relationship of these factors with the GPS. Elderly patients may tend to have worse nutritional status than younger patients, which may affect their albumin levels. Moreover, elderly patients are likely to have chronic disease that impairs their nutritional status and increases inflammatory reactions. Smoking status may provoke airway inflammation and might have been confounded with sex. Various diseases, such as chronic obstructive pulmonary disease, interstitial pneumonia and atherosclerosis, have been revealed to be closely associated with inflammation [18, 19] . In this study, the GPS and a-GPS were clearly associated with interstitial pneumonia, but not with other comorbidities (Table 2) . Discrepancies between the GPS and a-GPS were difficult to explain, but we think that variables showing significant differences in their association with the two scales may indicate the presence of high inflammation or poor nutrition. They might not be analysed appropriately because of the small number of patients affected.
The a-GPS showed a clearer classification of the prognosis in lung cancer surgery than the GPS. This finding may be due to our study population. We targeted operable-stage lung cancer patients, who may have less systemic inflammation and a better general condition than patients with advanced disease, who are sometimes cachectic. In fact, some studies focusing on advanced-stage cancer have reported a larger number of patients with GPS 2 than our cohort [2] [3] [4] . This characteristic of our cohort may also be one reason why the survival curves separated as time passed. Surgical candidates must seldom have poorly controlled comorbidities or untreatable lung cancers, both of which can be causes of early postoperative death.
The NLR and PLR showed some correlation with the GPS and the a-GPS (Table 1 ). These inflammation-based scores may reflect common phenomena in patients' bodies, because inflammatory reactions are likely to cause concurrent elevations of multiple inflammatory parameters [13] . However, in some ways, the NLR and PLR seemed to differ from the GPS and the a-GPS. We analysed the relationships between patient characteristics and the NLR and PLR (Tables 6 and 7) . Unlike the GPS and the a-GPS, the NLR and the PLR did not differ statistically in terms of age, sex, smoking status, pathological stage, histological type or surgical procedure. These analyses suggest that each of the inflammation-based scores may have similar but different characteristics.
The estimation of the GPS uses inexpensive and routinely available laboratory data. Moreover, the calculation of the GPS is very simple and can be judged quickly. We therefore think that the GPS is a valuable tool that should be utilized in daily clinical practice for the consideration of optimal treatment strategies. When a patient with early-stage lung cancer has a high GPS, they may have poorly controlled underlying disease, and their general condition should be carefully checked preoperatively.
There were some limitations in this study. The study design was retrospective, observational and single-institutional. Our results might be biased by patient selection, because this study included only surgically treated patients. The clinical use of the GPS should therefore be studied further in the future.
In conclusion, the GPS is an independent prognostic factor for the OS in lung cancer surgery. The optimal cut-off values for GPS estimation may need to be re-evaluated in patients with resectable lung cancer. Mantel-Haenszel test using the group mean score (ANOVA-type).
